Swiss CDMO Lonza has completed a planned laboratory expansion at its active pharmaceutical ingredients (API) manufacturing site at Nansha, China and plans to begin...
Swiss CDMO Lonza has agreed a five-year collaboration on the development and manufacturing of biologics and small molecules with European venture capital firm Bioqube...
CDMO Lonza is adding microbial development capabilities at its Visp, Switzerland, site. The company said the investment will support a capacity increase services...
Swiss specialty chemicals producer Arxada, which was recently sold by CDMO Lonza to private equity funds Bain Capital and Cinven, has made its first strategic move since...
Swiss CDMO Lonza is making major strides to expand its position in exosome manufacturing. This week it announced two new moves. In the first, it will acquire and operate...
The former Lonza division LSI, a specialty chemicals company active in Microbial Control Solutions (MCS) and Specialty Products Solutions (SPS), will operate under the...
Swiss CDMO Lonza and Danish clinical-stage pharma Allarity Therapeutics have agreed to develop and manufacture anti-cancer therapy dovitinib. The companies are aiming to...
